Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects.

Trial Profile

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Peanut allergy immunotherapy (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Sponsors DBV Technologies
  • Most Recent Events

    • 25 Feb 2016 Results published in DBV Technologies media release.
    • 25 Feb 2016 According to DBV Technologies media release, results of this trial is published in the Journal of Allergy and Clinical Immunology (JACI).
    • 18 Jun 2012 Full results were reported at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI), and in a DBV Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top